EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form

Vivek Purohit iD, Kazuko Sagawa iD, Hao-Jui Hsu iD, Joseph Kushner, Martin E Dowty iD, Susanna Tse iD, Jian Lin, Andrew Blanchard, Arnab Mukherjee iD, Vu Le, Cheng Chang iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Vivek Purohit und 10 weiteren Autor:innen. Beteiligte Einrichtung: Translational Clinical Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut, USA. Hauptthemen laut MEDLINE: Microspheres, Models, Biological, Piperidines, Pyrimidines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome's set of protein kinases. Currently approved formulations for tofacitinib citrate are immediate‐release (IR) tablets, modified‐release (MR) tablets, and IR solution. A once daily MR microsphere formulation was developed for use in pediatric patients. Demonstration of bioequivalence (BE) between the 10 mg once daily (q.d.) MR microsphere formulation and 5 mg twice daily (b.i.d.) IR solution is needed to enable the exposure–response analyses‐based bridging to support regulatory approval. To assess BE between MR microsphere and IR solution, an innovative approach was utilized with physiologically‐based pharmacokinetic (PBPK) virtual BE trials (VBE) in lieu of a clinical BE trial. A PBPK model was developed to characterize the absorption of different formulations of tofacitinib using Simcyp ADAM module. VBE trials were conducted by simulating PK profiles using the verified PBPK model and integrating the clinically observed intrasubject coefficient of variation (ICV) where BE was assessed with a predetermined sample size and prespecified criteria. The VBE trials demonstrated BE between IR solution 5 mg b.i.d. and MR microsphere 10 mg q.d. after a single dose on day 1 and after multiple doses on day 5. This research presents an innovative approach that incorporates clinically observed ICV in PBPK model‐based VBE trials, which could reduce unnecessary drug exposure to healthy volunteers and streamline new formulation development strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicrospheresModels, BiologicalPiperidinesPyrimidinesTherapeutic EquivalencyAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultComputer SimulationCross-Over StudiesDelayed-Action PreparationsDrug Administration ScheduleJanus Kinase InhibitorsProtein Kinase InhibitorsPyrrolesTablets

Substanzen

Delayed-Action PreparationsJanus Kinase InhibitorsPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolesTabletstofacitinib

Autor:innen und Institutionen

  • Translational Clinical Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut, USA.
  • Pharmaceutical Science, Drug Product Design, Pfizer Worldwide Research and Development, Groton, Connecticut, USA.
  • Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA.
  • Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA.
  • Pharmaceutical Science, Analytical Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut, USA.
  • Global Biometrics and Data Management, New York, New York, USA.

ORCID-Profile: Vivek Purohit, Kazuko Sagawa, Hao-Jui Hsu, Martin E Dowty, Susanna Tse, Arnab Mukherjee, Cheng Chang

Zitieren

APA

Purohit, V., Sagawa, K., Hsu, H. J., Kushner, J., Dowty, M. E., Tse, S., Lin, J., Blanchard, A., Mukherjee, A., Le, V., & Chang, C. (2024). Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3313

Vancouver

Purohit V, Sagawa K, Hsu HJ, Kushner J, Dowty ME, Tse S, et al. Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3313

BibTeX
@article{Purohit2024,
  author = {Purohit, Vivek and Sagawa, Kazuko and Hsu, Hao-Jui and Kushner, Joseph and Dowty, Martin E and Tse, Susanna and Lin, Jian and Blanchard, Andrew and Mukherjee, Arnab and Le, Vu and Chang, Cheng},
  title = {Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3313}
}
Kostenlos starten →